Current treatment options in oncology
The most recent articles from:
December 2013
-
Curr Treat Options Oncol · Dec 2013
ReviewBevacizumab in advanced NSCLC: chemotherapy partners and duration of use.
Bevacizumab is an effective targeted therapy with demonstrated survival benefits for many patients with advanced nonsquamous non-small cell lung cancer (NSCLC). Some patient populations are at higher risk for bleeding complications and bevacizumab should be avoided, but advanced age should not be used as the sole exclusion criterion for use. ⋯ The optimal maintenance strategy is yet to be determined and is the focus of ongoing trials, such as ECOG 5508. Early use of bevacizumab in the adjuvant setting and continued use in the second-line setting are being investigated in current clinical trials.